Stephen Gottschalk, MD
Stephen Gottschalk, MD

Stephen Gottschalk, MD

Member, St. Jude Faculty

  • Chair, Department of Bone Marrow Transplantation & Cellular Therapy
  • Endowed Chair in Bone Marrow Transplantation & Cellular Therapy



MD - Georg August University, Göttingen, Germany
Pediatric Internship
- University of Münster, Germany
Pediatric Residency
- Baylor College of Medicine, Houston, Texas
Pediatric Hematology-Oncology Fellowship
- Baylor College of Medicine, Houston, Texas

Honors & Awards

  • 2015  American Society of Clinical Investigation

Research Interests

  • Cancer immunotherapy
  • Cell therapy
  • Stem cell transplantation

Selected Publications


Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O’Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36(11):1128-1139, 2018.

Pituch KC, Miska J, Krenciute G, Panek WK, Li G, Rodriguez-Cruz T, Wu M, Han Y, Lesniak MS, Gottschalk S, Balyasnikova IV. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma. Mol Ther 26(4):986-995, 2018.


Mata M, Gerken G, Nguyen P, Krenciute G, Spencer MD, Gottschalk S. Inducible activation of MyD88 and CD40 in CAR T-cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discovery 7(11):1306-1319, 2017.

Krenciute G, Brooke LP, Yi Z, Wu MF, Hao L, Dotti G, Balyasnikova IV, Gottschalk S. Transgenic expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells but results in antigen-loss variants. Cancer Immunol Res 5(7):571-581, 2017.

Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Lee B, Gottschalk S, Brenner M, Suzuki M. Armed oncolytic adenovirus expressing PD-L1 mini-body enhances anti-tumor effects of chimeric antigen receptor T-cells in solid tumors. Can Res 77(8):2040-2051, 2017.

Ahmed N,  Brawley V,  Bielamowicz K, Hegde M,  Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu M-F, Liu H, Rooney CM, Dotti G, Gee A, Su J,  Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-specific Chimeric Antigen Receptor–modified virus-specific T-cells for progressive Glioblastoma: a Phase I dose-escalation Trial. JAMA Oncol 3(8):1094-1101, 2017.


Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J Clin Invest 126(8):3036-52, 2016.

Bonifant CL, Szoor A, Torres D, Joseph N, Velasquez MP, Iwahori K, Gaikwad A, Nguyen P, Arber C, Song XT, Redell M, Gottschalk S. CD123-Engager T cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther 24(9):1615-2, 2016.

Velasquez MP, Torres D, Iwahori K, Kakarla S, Arber C, Rodriguez-Cruz T, Szoor A, Bonifant CL, Gerken C, Cooper LJN, Song X-T, Gottschalk S. T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies. Sci Rep 6:27130, 2016.

Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S. Characterization and functional analysis of scFv-based CARs to redirect T cells to IL13R2-positive glioma. Mol Ther 24(2):354-63, 2016.


Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. HER2-specific Chimeric Antigen Receptor-modified T cells for the Immunotherapy of HER2-positive Sarcoma. J Clin Oncol 33(15):1688-96, 2015.

Wakefield A, Pignata A, Ghazi A, Ashoori A, Hegde M, Landi D, Gray T, Scheurer ME, Chintagumpala M, Adesina A, Gottschalk S, Hicks J, Powell SZ, Ahmed N. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients. J Neurooncol. 125(2):307-15, 2015.

Zhu S, Denman CJ, Cobanoglu ZS, Kiany S, Lau CC, Gottschalk SM, Hughes DP, Kleinerman ES, Lee DA. The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. Pharm Res Mar;32(3):779-92, 2015.

Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Engager T cells: A new class of antigen-specific T cells that redirect bystander T cells. Mol Ther Jan;23(1):171-8, 2015.

Last update: April 2018